Loading…
NRx Pharmaceuticals, Inc. is projected to rise to $4.22 by 2027, a +34% move from its current price of $3.15. NRXP is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/3/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 4 | $3.03 | $3.15 | $3.29 | +0.12% |
| Aug 5 | $2.98 | $3.16 | $3.35 | +0.23% |
| Aug 6 | $2.94 | $3.16 | $3.40 | +0.35% |
| Aug 7 | $2.91 | $3.16 | $3.44 | +0.46% |
| Aug 8 | $2.89 | $3.17 | $3.48 | +0.58% |
| Aug 9 | $2.87 | $3.17 | $3.51 | +0.70% |
| Aug 10 | $2.85 | $3.18 | $3.54 | +0.81% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.85 | $3.18 | $3.54 | +0.81% |
| Week 2 | $2.74 | $3.20 | $3.74 | +1.63% |
| Week 3 | $2.67 | $3.23 | $3.90 | +2.46% |
| Week 4 | $2.61 | $3.25 | $4.05 | +3.29% |
| Week 5 | $2.57 | $3.28 | $4.19 | +4.13% |
| Week 6 | $2.53 | $3.31 | $4.33 | +4.98% |
| Week 7 | $2.49 | $3.33 | $4.46 | +5.83% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on therapies for central nervous system disorders in the United States. It operates through NRx and Dura segments and develops NRX-101, an oral fixed-dose combination of D-cycloserine (DCS) and lurasidone in Phase 2/3 for bipolar depression with sub-acute ideation and behavior; NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression; and KETAFREE, a generic preservative-free formulation of ketamine.
It also provides precision-based interventional psychiatry services to patients using a combination of neuroplastic drugs, transcranial magnetic stimulation (TMS), digital therapeutics, and hyperbaric therapy; ketamine infusion therapy; stellate ganglion blocks; Spravato administration; psychotherapy; and medication management. The company has a development and license agreement with Glytech LLC. NRx Pharmaceuticals, Inc.
was founded in 2015 and is headquartered in Wilmington, Delaware.
NRx Pharmaceuticals, Inc. trades under the symbol NRXP. The current price is $3.23 and the market cap is $138.25M, with a rank of 4029. These figures place the stock in the small-cap healthcare segment.
The forecasted price path through 2026-2050 shows rising averages: 2026 avg $3.23, 2027 $4.34, 2028 $4.75, 2029 $5.56, 2030 $5.32, 2031 $6.59, 2032 $9.23, 2033 $9.93, 2034 $11.40, 2035 $10.90, 2040 $19.95, 2050 $45.00. The max values rise to $5.05 in 2026, $6.19 in 2027, $7.15 in 2028, $8.74 in 2029, $8.65 in 2030, $11.05 in 2031, $15.90 in 2032, $17.52 in 2033, $20.57 in 2034, $20.06 in 2035, $39.95 in 2040, and $101.53 in 2050. The ROIs align with growth, reaching 64.7 by 2030, 517.6 by 2040, and 1293.2 by 2050.
A major floor 33.7% below — a decisive break under it would weaken the trend.
Price is testing support right now (1.0% away) — a key level to hold.
The nearest ceiling, 42.2% above — a clean break opens room to run.
A major ceiling 56.9% above — clearing it would confirm fresh momentum.
Key NRXP support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of NRXP market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $3.33 | Sell | $3.35 | Sell |
| MA 10 | $3.77 | Sell | $3.60 | Sell |
| MA 20 | $3.97 | Sell | $3.80 | Sell |
| MA 50 | $3.95 | Sell | $3.74 | Sell |
| MA 100 | $3.24 | Sell | $3.41 | Sell |
| MA 200 | $2.78 | Buy | $3.06 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 33.17 | Neutral |
| Stoch RSI (14) | 3.00 | Buy |
| CCI (20) | -157.10 | Sell |
| Williams %R (14) | -97.79 | Info |
| MACD (12,26,9) | -0.14 | Sell |
| ROC (12) | -29.37 | Sell |
| Bollinger %B (20,2) | 0.01 | Neutral |
| Stochastic %K (14) | 2.21 | Buy |
| TRIX (15) | -0.04 | Sell |
| Awesome (5,34) | -0.60 | Sell |
| Ultimate (7,14,28) | 15.31 | Buy |
| Momentum (10) | -1.12 | Sell |
| Aroon Osc (25) | -24.00 | Sell |
| Hull MA (9) | 2.98 | Buy |
| ADX (14) | 19.20 | Neutral |
| ATR (14) | 0.16 | Info |
The 30-day technical picture shows a bullish tilt with RSI14 at 30. The stock trades around the SMA50 of $3.95 and above the SMA200 of $2.78, suggesting a positive alignment. Support is at $3.23 and resistance at $4.48, with a 30-day price range from $2.42 to $4.30. Annualized volatility stands at 80%, indicating notable price movement potential.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.68 | $3.15 | $4.89 | 0% | Neutral | |
| $3.21 | $4.22 | $5.96 | +34% | Bullish | |
| $3.35 | $4.61 | $6.86 | +46% | Bullish | |
| $3.82 | $5.46 | $8.47 | +73% | Bullish | |
| $3.55 | $5.25 | $8.42 | +67% | Bullish | |
| $4.23 | $6.45 | $10.66 | +105% | Bullish | |
| $5.73 | $9.02 | $15.29 | +186% | Bullish | |
| $5.98 | $9.68 | $16.80 | +207% | Bullish | |
| $6.69 | $11.12 | $19.71 | +253% | Bullish | |
| $6.33 | $10.79 | $19.52 | +243% | Bullish | |
| $10.07 | $19.42 | $38.11 | +516% | Bullish | |
| $19.95 | $44.34 | $97.77 | +13.1x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $1.68 | $3.15 | $4.11 | +0.00% |
| September 2026 | $2.84 | $3.41 | $4.24 | +8.24% |
| October 2026 | $2.88 | $3.50 | $4.43 | +2.67% |
| November 2026 | $3.05 | $3.73 | $4.78 | +6.52% |
| December 2026 | $3.06 | $3.77 | $4.89 | +1.22% |
Click any year to see its month-by-month NRXP forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect NRXP to range from $1.68 to $4.89 through 2026. The $3.15 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The NRXP price prediction for 2027 points to an average of $4.22 (low $3.21, high $5.96) — a potential gain of +34% on today's $3.15. Momentum favours further upside here.
In 2028, NRXP is projected to trade between $3.35 and $6.86, averaging $4.61 — a potential gain of +46% from today's $3.15. That is up +9% on the projected 2027 average. Buyers look set to stay in control over this stretch.
NRx Pharmaceuticals, Inc.'s 2029 outlook centres on $5.46, within a $3.82 to $8.47 range. That is up +18% on the projected 2028 average. That marks a +73% change versus current levels. Momentum favours further upside here.
By 2030, NRXP could reach as high as $8.42, with a base case around $5.25 and support toward $3.55 — roughly +67% from $3.15. Buyers look set to stay in control over this stretch.
Expect NRXP to range from $4.23 to $10.66 through 2031. The $6.45 average target implies a +105% move from current prices. That is up +23% on the projected 2030 average. Momentum favours further upside here.
The NRXP price prediction for 2032 points to an average of $9.02 (low $5.73, high $15.29) — a potential gain of +186% on today's $3.15. Buyers look set to stay in control over this stretch.
In 2033, NRXP is projected to trade between $5.98 and $16.80, averaging $9.68 — a potential gain of +207% from today's $3.15. That is up +7% on the projected 2032 average. Momentum favours further upside here.
NRx Pharmaceuticals, Inc.'s 2034 outlook centres on $11.12, within a $6.69 to $19.71 range. That is up +15% on the projected 2033 average. That marks a +253% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, NRXP could reach as high as $19.52, with a base case around $10.79 and support toward $6.33 — roughly +243% from $3.15. Momentum favours further upside here.
Expect NRXP to range from $10.07 to $38.11 through 2040. The $19.42 average target implies a +516% move from current prices. That is up +80% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The NRXP price prediction for 2050 points to an average of $44.34 (low $19.95, high $97.77) — a potential gain of +13.1x on today's $3.15. Momentum favours further upside here.
Investing $1,000 in NRXP today (≈ 317.460317 NRXP) could be worth
$14,076.75
+$13,076.75 (+1308%) by 2050 · US Dollar
Based on the average projected NRXP price of $44.34 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in NRXPwould be worth at today's price.
$1,000 invested in NRXP on Jul 31, 2025 (≈ 371.747204 NRXP) would be worth
$1,171
+$171 (+17.1%) today · 1.17× · US Dollar
Based on a NRXP entry price of $2.69 vs. today's $3.15.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $3.75 | $840 | -16.0% |
| 1 month ago | $3.86 | $816.06 | -18.4% |
| 3 months ago | $3.09 | $1,019.42 | +1.9% |
| 6 months ago | $2.15 | $1,465.12 | +46.5% |
| 1 year ago | $2.69 | $1,171 | +17.1% |
| All time (5.0y) ago | $146.6 | $21.49 | -97.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our NRXP forecast.
Our base-case forecast reaches $6.30 around 2031.
Implied market cap at $6.30: $269.64M
The multi-year forecast is bullish across many years, with 2026 min $1.68, avg $3.23, max $5.05 and 0 as ROI, and 2027 min $3.27, avg $4.34, max $6.19 with ROI 34.4. It shows rising averages through 2029 and 2030 (2030 avg $5.32, ROI 64.7), followed by continued gains into 2031-2035 (2031 avg $6.59; 2032 $9.23; 2033 $9.93; 2034 $11.40; 2035 $10.90). The longer horizon accelerates with 2040 avg $19.95 (ROI 517.6) and 2050 avg $45.00 (ROI 1293.2).
These figures imply substantial upside but remain estimates and are not guarantees.
Tap a question to reveal the answer.
According to the forecast, the 2030 average price is $5.32 with a min of $3.54 and a max of $8.65; the associated ROI is 64.7 and the sentiment is BULLISH.
The forecast shows bullish sentiment in multiple years and strong upside by 2040 ($19.95 avg) and 2050 ($45.00 avg) with the 2050 max of $101.53. However, these figures are estimates and not guarantees.
The max forecast in 2050 is $101.53, indicating a potential to surpass $100 in that year.
RSI14 is 30, SMA50 is $3.95, SMA200 is $2.78. The price sits at $3.23 with support at $3.23 and resistance at $4.48, and the 30-day range is $2.42–$4.30.
The current price is $3.23 and the market cap is $138.25M, with a rank of 4029.
NRx Pharmaceuticals, Inc. Community Discussion
0Share your NRx Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.